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ingle nucleotide polymorphisms (SNPs)
aplotype
a b s t r a c t
Malignant pleural mesothelioma (MPM) is a rare aggressive tumor associated with asbestos exposure.
The possible role of genetic factors has also been suggested and MPM has been associated with single
nucleotide polymorphisms (SNPs) of xenobiotic and oxidative metabolism enzymes. We have identi-
fied an association of the DNA repair gene XRCC1 with MPM in the population of Casale Monferrato,
a town exposed to high asbestos pollution. To extend this observation we examined 35 SNPs in 15
genes that could be involved in MPM carcinogenicity in 220 MPM patients and 296 controls from two
case–control studies conducted in Casale (151 patients, 252 controls) and Turin (69 patients, 44 con-
trols), respectively. Unconditional multivariate logistic regression was used to estimate odds ratios (ORs)
and 95% confidence intervals (95% CIs). Two DNA repair genes were associated with MPM, i.e. XRCC1
and ERCC1. Considering asbestos-exposed only, the risk increased with the increasing number of XRCC1-
399Q alleles (Casale: OR = 1.44, 95%CI 1.02–2.03; Casale + Turin: OR = 1.34, 95%CI 0.98–1.84) or XRCC1
−77T alleles (Casale + Turin: OR = 1.33, 95%CI 0.97–1.81). The XRCC1-TGGGGGAACAGA haplotype was
significantly associated with MPM (Casale: OR = 1.76, 95%CI 1.04–2.96). Patients heterozygotes for ERCC1
N118N showed an increased OR in all subjects (OR = 1.66, 95%CI 1.06–2.60) and in asbestos-exposed only
(OR = 1.59, 95%CI 1.01–2.50). When the dominant model was considered (i.e. ERCC1 heterozygotes CT
plus homozygotes CC versus homozygotes TT) the risk was statistically significant both in all subjects
(OR = 1.61, 95%CI 1.06–2.47) and in asbestos-exposed only (OR = 1.56, 95%CI 1.02–2.40). The combina-
tion of ERCC1 N118N and XRCC1 R399Q was statistically significant (Casale: OR = 2.02, 95%CI 1.01–4.05;
95%C
sed sCasale + Turin: OR = 2.39,
hypothesis that an increa
. IntroductionMalignant mesothelioma (MM) is a rare and aggressive tumor
hat arises from mesothelial cells. Most frequent locations are in
he order pleura (malignant pleural mesothelioma, MPM) and peri-
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027-5107/$ – see front matter © 2011 Elsevier B.V. All rights reserved.
oi:10.1016/j.mrfmmm.2011.01.001I 1.29–4.43). The association of MPM with DNA repair genes support the
usceptibility to DNA damage may favour asbestos carcinogenicity.
© 2011 Elsevier B.V. All rights reserved.
toneum. In Western Europe, 5000 patients die of MM each year. In
countries where asbestos use has been discountinued or banned,
the incidence of MM is increasing and it is expected to peak in
the year 2020 [1]. Asbestos represents the main risk factor for the
development of MM, but its mechanisms of carcinogenicity are not
fully understood. Asbestos fibers could interfere with the mitotic
spindle formation of cells resulting in chromosomal abnormalities
[2]. Asbestos can also lead to the generation of reactive oxygen


























































2 M. Betti et al. / Mutation
he fibers or during frustrated phagocytosis [3]. Asbestos-induced
xidative damage has been clearly demonstrated, both in vitro and
n vivo. Its consequences include DNA single-strand breaks and DNA
ase modifications [4]. Moreover asbestos fibers may induce signal
ransduction (i.e. activation of NF-KB pathway [5]) and methylation
f gene promoters [6].
According to the Italian Mesothelioma Register, that collects
ata from over 2500 patients, the median latency period between
he time of initial asbestos exposure and the development of MPM
as about 45 years [7]. The male:female ratio was approximately
:1, likely due to occupational exposure [8]. Eighty per cent of MPM
atients have a history of asbestos exposure, but only 2% to 10% of
he individuals with heavy, prolonged asbestos exposure develop
PM [9]. The combined role of genetics and asbestos exposure in
amilial aggregation is debated [10–12] and has been discussed
n two extensive literature reviews [13,14]. Several genetic asso-
iation studies addressed the identification of the traits that may
redispose to asbestos damage susceptibility and MPM [15]. We
ere the first group to report an association between XRCC1 399Q
ariant and MPM and to suggest a role of deficient DNA repair in
PM carcinogenesis [16]. In the present paper, we expand the anal-
ses to 35 single nucleotide polymorphisms (SNPs) in 15 genes
ossibly involved in asbestos carcinogenicity (i.e. DNA repair, redox
tate control and inflammation). Our data highlight a significant
ssociation of MPM with two DNA repair genes, i.e. XRCC1 and
RCC1.
. Material and methods
.1. Study subjects
.1.1. Casale Monferrato panel
We conducted a population based case–control study on MPM
ithin the Local Health Authority (LHA) of Casale Monferrato. This
rea was characterized by widespread exposure to asbestos in the
eneral population because of an asbestos cement factory that had
een active from 1907 to 1986 [17].
The case group included subjects with histologically diagnosed
PM, resident in the LHA of Casale Monferrato, who were recruited
etween January 2001 and December 2006. Two controls per
atient, matched for age (±18 months) and gender, were ran-
omly selected from the local population using the rosters of the
HA of Casale Monferrato. Trained personnel submitted a standard
uestionnaire to MPM cases and controls to collect information
bout demographic variables, life-style, occupational history and
sbestos exposure [17]. The evaluation of asbestos exposure was
onducted blindly by an industrial hygienist (D. Mirabelli) and
ummarized as: “certain occupational”, “probable occupational”,
possible occupational”, “household exposure”, “environmental
xposure” and “no evidence of exposure”. Exposure was further
onsidered as a binary variable (exposed versus non-exposed). All
ubjects in the study signed an informed consent form before the
nterview. Blood samples were collected before therapy in vacu-
ainers with ethylenediaminetetraacetic acid (EDTA) and stored at
20 ◦C until use.
Ninety-four cases and three hundred controls refused to gave
heir blood sample. Consequently, the study involved 151 MPM
atients and 252 population controls. Table 1 summarizes the main
haracteristics of patients and controls who participated in the
tudy. All participants were caucasians with the same ethnic origin,
valuated by place of birth..1.2. Turin panel
We also conducted a hospital-based case–control study on MPM
n the Turin area. The case group included subjects with a histolog-arch 708 (2011) 11–20
ically confirmed diagnosis of MPM, admitted to the chest surgery
units of the San Giovanni Battista (Turin) or the San Luigi Gonzaga
(Orbassano) hospitals between January 2004 and October 2008. All
cases were resident in Turin or in the province of Turin at the time
of diagnosis. After case identification, control was chosen among
inpatients within the same hospital (mostly in the general medicine
or urology units) of the corresponding case, and had to live in Turin
or in the province of Turin at the time of admission and were not
affected by neoplastic or respiratory conditions. All study subjects
were Caucasians. Patients and controls were interviewed using the
same questionnaire described above. Asbestos exposure was eval-
uated as for the Casale group. All subjects in the study signed an
informed consent form. Blood samples were collected and stored
as reported above.
We had planned to select one control per patient matched
by age (±24 months) and gender, but no eligible control
was found for 25 cases. Thus, the study involved 69 MPM
patients and 44 controls. Table 1 summarizes the main char-




SNPs were chosen because some have a significant effect on the
transcript (i.e. amino acid substitution or possible splice defect)
and/or have been associated with certain cancer types and/or defi-
cient DNA repair [18–25].
In detail, 10 out of 15 genes (14 SNPs) are involved in the repair
of DNA damage. Our working hypothesis is that the presence of
polymorphic variants could reduce the efficiency of the DNA repair
machinery. The unrepaired DNA damage caused by asbestos expo-
sure would result in mutagenesis and cancer.
The SEP15 gene (one SNP) was analyzed because the encoded
selenoprotein is downregulated in 60% MPM cell lines [26].
Moreover, we evaluated two genes (two SNPs) involved in the
control of the cellular redox state (SOD2, GPX1). In this case, our
working hypothesis was that a reduced protection from ROS could
predispose mesothelial cells to neoplastic transformation.
Our study included also the OPN gene (three SNPs) that encodes
an inflammatory cytokine, since a higher susceptibility to inflam-
mation might be a risk factor for mesothelioma. High plasma OPN
levels have been considered a marker of MPM [27].
For haplotype analyses we studied nine SNPs in XRCC1 and six
SNPs in ERCC1 and its adjacent gene RAI: these SNPs were reported
as tag SNPs by Haploview v4.1 on HapMap CEU panel, release #24.
2.2.2. SNP analysis
Genomic DNA was isolated and purified from peripheral blood
lymphocytes using QIAamp® DNA Blood Maxi Kit (QIAGEN).
We used different genotyping approaches to analyze SNPs
involved in the study (Table 2). Most of the polymorphisms
(rs1799782, rs3213247, rs12973352, rs2854496, 2307174,
rs2023614, rs1799778, rs3213356, rs3213371, rs3213403,
rs1799796, rs1799793, rs11615, rs2298881, rs3212948,
rs3212965, rs3136820, rs12917, rs3626, rs10412761, rs4803817,
rs6966) were genotyped with the PCR-based fluorescence 5′
exonuclease assay (TaqMan® Genotyping Master Mix, Applied
Biosystems). The other polymorphisms (rs25487, rs3213245,
rs861539, rs13181, rs1052133, rs1805794, rs101028, rs7687316,
rs45594140, rs9138, rs1799725, rs1050450, rs1136410) were
genotyped with the SNaPshot assay (SNaPshot® Multiplex Kit,
Applied Biosystems) that uses a multiplex primer extension
technique and primers of different length to analyze at the same
time up to eight/ten SNPs.
M. Betti et al. / Mutation Research 708 (2011) 11–20 13
Table 1
Characteristics of cases and controls in the study.
Casale Monferrato Turina
Cases (%) Controls (%) Cases (%) Controls (%)
Eligible 245 (100%) 552 (100%) 201 (100%) 44 (100%)
Blood sample given 151 (62%) 252 (46%) 69 (34%) 44 (100%)
Blood sample refuseda 94 (38%) 300 (54%) 132 (66%) 0
Samples included in the analyses 151 (100%) 252 (100%) 69 (100%) 44 (100%)
Gender
Males 101 (67%) 173 (69%) 48 (70%) 34 (77%)
Females 50 (33%) 79 (31%) 21 (30%) 10 (23%)
Age (mean ± standard deviation) 66.8 ± 11.5 61.7 ± 11.1 68.9 ± 8.4 68 ± 8.7
Histology
Epithelioid 102 (68%) 48 (70%)
Sarcomatous 14 (9%) 8 (12%)
Mixed 31 (21%) 10 (14%)
Undefined 2 (1%) 3 (4%)
Missing 2 (1%) 0
Asbestos exposure
Occupational 71 (47%) 111 (44%) 54 (78%) 18 (41%)
Domestic 26 (17%) 24 (10%) 4 (6%) 2 (5%)
Environmental 34 (23%) 59 (23%) 9 (13%) 5 (11%)
T
S
Not exposed 2 (1%)
Undefined 18 (12%)
a Turin study: no eligible control refused blood sample, but 132 cases had confirmation o
able 2
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Fig. 1. XRCC1 tag SNPs (TAG SNPs are loci that capture most of the genetic vari-



























NPs needed to detect LD-based association between a trait of interest and a region
f the genome.) identified using Haploview v4.1. 01: rs3213403; 10: rs3213371;
0: rs3213356; 23: rs1799778; 34: rs2023614; 37: rs2307174; 50: rs2854496; 68:
s12973352; 81: rs3213247.
.2.3. Quality control
For each SNP, samples with the three genotypes (i.e. homozy-
ous for the wild-type sequence, heterozygous and homozygous
or rarer sequence) were directly sequenced and used as internal
ontrol in each analysis. Ten per cent of samples were randomly
equenced. Concordance was 100% for all comparisons.
.3. Sequencing
We sequenced the seventeen exons and exon–intron bound-
ries of XRCC1 in ten wild-type homozygous, in ten heterozygous
nd in ten variant homozygous for SNP R399Q using ABI PRISM
100 Genetic Analyzer (Applied Biosystems).
.4. Haplotype analysis
By using Haploview v4.1 [28] and the HapMap-CEU panel geno-
ype data (release #24) we identified nine different SNPs as XRCC1
ag-SNPs and six different SNPs as ERCC1 RAI tag-SNPs (Figs. 1 and 2,
espectively).
The haplotypes of XRCC1 and ERCC1 RAI were inferred by
HEsis software platform [29]. Haplotype frequency and corre-
ponding standard deviation was obtained from genotype data
f each polymorphism with unknown genetic phase, using max-
mum likelihood estimation. The analyses were performed using
APLO.STATS software package developed using the R language.
dds ratios (ORs) and 95% confidence intervals (95%CIs) were cal-
ig. 2. ERCC1 RAI tag SNPS identified using Haploview v4.1. 01: RAI rs6966; 04: RAI
s4803817; 05: RAI rs10412761; 10: ERCC1 rs3212965; 15: ERCC1 rs3212948; 16:
RCC1 rs2298881.arch 708 (2011) 11–20
culated after estimating the number of patients and controls for
each haplotype, considering the most frequent haplotype as ref-
erence. These analyses were carried out both in the overall sample
and in the subgroup of subjects with asbestos exposure. All analyses
were adjusted for age and gender.
2.5. XRCC1 expression
Seventy-one samples of normal pleura were obtained from
donors that were subjected to thoracoscopy for a condition dif-
ferent from MPM and signed an informed consent.
Total RNA was extracted from frozen, normal pleural tissues by
RNeasy® Plus Mini Kit (QIAGEN) according to the manufacturer’s
protocol.
cDNA was retrotranscribed from 500 ng of total RNA using
random primers (High Capacity cDNA Reverse Transcription Kit,
Applied Biosystems).
The levels of mRNA were measured by quantitative real-time
PCR (qPCR).
Relative gene expression quantification for XRCC1 and the ref-
erence gene UBC was carried out in triplicate, with TaqMan®
chemistry using ABI Prism 7000 Sequence Detection System
(Applied Biosystems). Primers and probes used to quantify the tran-
scripts of XRCC1 and UBC were Taqman gene expression assays
(Applied Biosystems).
After initial denaturation at 95 ◦C for 10 min, the reaction pro-
ceeded with 40 cycles of 95 ◦C for 15 s and 60 ◦C for 1 min. To assess
variation between experiments, a standard cDNA was included in
each plate. The analyses were carried out using the comparative
CT method [30]. The threshold cycle (CT), is defined as the number
of cycles required for the fluorescent signal to cross the threshold
(i.e. exceeds background level). CT levels are inversely proportional
to the amount of mRNA in the sample (i.e. the lower CT level the
greater the amount of mRNA in the sample).
CT level was determined for each gene and the relative expres-
sion of XRCC1 was then estimated by calculating the dCT value,
defined as the difference in the CT value for the target gene (XRCC1)
and the reference gene (UBC).
2.6. Statistical analysis
To evaluate the hypothesis of association between genetic
polymorphisms and MPM, unconditional multivariate logistic
regression method was used. ORs and 95%CIs were calculated
for each genotype compared to the reference group, that is the
homozygous for the more frequent allele among controls. Each SNP
was considered in separate analyses as both a categorical variable
(i.e. wild-type homozygous, heterozygous and variant homozy-
gous) and a continuous variable (number of mutated alleles).
Genotypes were also divided into two categories (risk versus non-
risk genotypes) on the basis of literature (i.e. prior knowledge of the
functional significance of the variants and existing epidemiological
evidence) and of our data. In particular, XRCC1 399Q (rs25487) was
considered a risk factor under a dominant model [16,31], whereas
−77C (rs3213245) was considered a protective factor under a dom-
inant model (our data).
For the analysis of the combination of XRCC1 R399Q and ERCC1
N118N polymorphisms, subjects were categorized according to the
cumulative number of variant alleles.
The analyses were carried out both in overall sample and in
the subgroup of subjects with asbestos exposure. All analyses were
adjusted by age, gender and asbestos exposure for overall sample,
and by age and gender for the asbestos-exposed subjects. The anal-
yses were performed using SAS v.8.01 and the SNPassoc software



























































M. Betti et al. / Mutation
Since several of the SNPs that were studied in this work were
he object of two previous papers [33,34], we also carried out a
eta-analysis. Gemignani et al. [33] used two panels of controls:
anel 1 included individuals whose asbestos exposure was known,
hereas panel 2 included blood donors whose asbestos exposure
ad not been evaluated. We performed our meta-analysis using
anel 1 only, since these controls were more similar to our con-
rol group, and had detailed information about asbestos exposure.
eta-analysis was carried out using a variance based (fixed effects)
ethod. Study weights were proportional to the inverse variance
f the OR, estimated from the confidence interval [35].
As the SNPs considered in the study were selected in accordance
ith a well defined hypothesis supported by previous observa-
ions, we did not apply a correction for multiple testing. Instead,
e estimated the false-positive report probability (FPRP) using the
ayesian approach proposed by Wacholder et al. [36]. This method
equires the estimation (from previous biochemical or molecular
nformation and/or results from meta-analysis) of the prior proba-
ilities that the specific SNPs are associated with the disease under
tudy. We gave a high prior probability (0.2) when (a) the biological
lausibility was high, and (b) the existing epidemiologic evidence
f association with cancer was fair; a prior probability of 0.1 when
iological plausibility was high but the prior epidemiological evi-
ence was poor; a prior probability of 0.01 when both were poor
22]. The available epidemiologic evidence did not allow higher
rior probabilities [19].
Analysis of variance and t-test were used to determine differ-
nces in the XRCC1 mRNA relative expression levels (normalized




The main information on the cases and controls are reported in
able 1. The Casale Monferrato panel included 151 MPM patients
nd 252 population controls. Participation was not the same among
ases and controls. Overall 151/245 cases and 252/552 controls in
he Casale Monferrato panel agreed to donate a blood sample. That
roportion was influenced by gender (in controls more often men
ccepted and women refused -p < 0.05-, no gender differences were
bserved in cases) and age (in both cases and controls mean age for
articipating subjects was lower than for refusers, this difference
as statistically significant -p < 0.05- in controls). These figures
ere expected given the fact that blood sampling is an annoying
rocedure and it is less accepted in elderly women and in absence
f an health related need (as shown by a lower participation among
ome interviewed controls compared to hospital admitted cases).
o differences were observed by residence, thus participation was
ot associated to social pressure or exposure related feelings. As far
s to our knowledge, none of the variables considered and influenc-
ng participation is associated to the analyzed SNPs and therefore
ifferential participation cannot pose a confounding threat in the
resent study [37]. Almost all subjects were exposed to asbestos,
nly 23% of controls and 1% of cases were not exposed (12% of cases
ad an undefined asbestos exposure). The main asbestos exposure
as occupational both in cases (47%) and in controls (44%). Envi-
onmental asbestos exposure in the area accounts for the very large
roportion of exposed [38].The Turin panel, including 69 MPM patients and 44 controls,
erives from a hospital-based case–control study still under way.
he imbalance between the number of cases and controls, thus, is
ue to the fact that controls are recruited after cases, so that for part
f the MPM patients a suitable control had not been included yetarch 708 (2011) 11–20 15
at the time of analysis. Almost all cases were exposed to asbestos.
Only 1.5% were not exposed and 1.5% had an undefined asbestos
exposure. The 56% of controls were exposed to asbestos. The main
asbestos exposure was occupational both in cases (78%) and in
controls (41%).
3.2. SNP analysis
We analyzed 35 SNPs in 15 genes (10 DNA repair genes, 1
selenoprotein, 2 redox state genes, 1 inflammatory gene and 1
phosphatase gene), listed in Table 2. All polymorphisms were in
Hardy–Weinberg equilibrium both in cases and controls, except
ERCC2 rs13181 in Casale Monferrato controls, ERCC2 rs1799793 and
OPN rs7687316 in Turin controls. This may be due to the small size
of Turin panel or to chance.
In Casale Monferrato panel, 18 MPM patients were excluded
from statistical analyses because of an undefined asbestos expo-
sure. For the same reason one patient was excluded from Turin
panel. Data for XRCC1 R399Q and XRCC1 −77T>C are not available
in one control of Turin panel.
First statistical analyses were carried out considering separately
Casale Monferrato (133 MPM patients and 252 population controls)
and Turin (68 MPM patients and 44 controls), then the panels were
pooled (201 MPM patients and 296 controls). Moreover statisti-
cal analyses were performed in the subgroup of asbestos-exposed
subjects (Casale: 131 MPM patients and 194 controls; Turin: 67
MPM patients and 25 controls; Casale + Turin: 198 MPM cases and
218 controls). Overall data are included in Supplementary Table
S1, S2 and S3. The ORs for the statistically significant associations
are listed in Tables 3 and 4. In Casale Monferrato panel (Table 3),
when we considered only asbestos-exposed subjects, the risk of
MPM increased with the increasing number of XRCC1-399Q alleles
and results are statistically significant (OR = 1.44, 95%CI 1.02–2.03).
When the dominant model was considered (i.e. XRCC1 RQ het-
erozygotes plus QQ homozygotes versus RR homozygotes) the
association with MPM was borderline significant (OR = 1.50, 95%CI
0.98–2.28). When XRCC1 rs1799778 was considered as a continu-
ous variable the risk was statistically significant (OR = 1.43, 95%CI
1.02–2.01). This change is located in intron 3. A possible functional
role is not reported.
The present analysis includes the panel of patients and controls
evaluated in our previous paper [16]. If we exclude these subjects
the OR associated with XRCC1 -399Q in asbestos exposed individu-
als becomes 1.25 (95%CI 0.76–2.06), based on 55 patients and 109
controls.
Data from Turin panel never reached statistical significance
when considered separately, probably due to the small sample.
However, even if not significant, the retrieved information was
always consistent with that of Casale panel alone.
Considering the Casale Monferrato and Turin panels together
(Table 4), in asbestos-exposed individuals the association between
XRCC1 -399Q and MPM decreased and became only borderline
statistically significant (OR = 1.34, 95%CI 0.98–1.84). XRCC1 −77C
instead gave some indication of a protective effect with an OR = 0.52
(95%CI 0.27–1.01); though not statistically significant, this SNP
suggests a protective effect of the variant allele also when it is con-
sidered as a continuous variable (OR = 0.75, 95%CI 0.55–1.03) and
when the dominant model was considered (i.e. XRCC1 TC heterozy-
gotes plus TT homozygotes versus CC homozygotes (OR = 0.58,
95%CI 0.32–1.05).
The haplotype analysis performed by Haploview v4.1 on XRCC1
R399Q and XRCC1 −77T>C showed that they were in linkage dise-
quilibrium (LD) (D′ = 0.94; r2 = 0.27).
To ascertain whether the effect of the reported association was
due to a further variant in LD with the studied SNPs we then
sequenced the coding and promoter region of XRCC1. Several doc-
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Table 3
Odds ratios (ORs) and 95% confidence intervals (95%CIs) from multivariate unconditional logistic regression adjusted by age, gender and asbestos exposure for all subjects,
and by age and gender for the asbestos-exposed subjects in the Casale Monferrato panel.
Gene SNP (rs) Cases (%)a Controls (%) OR (95%CI) Cases (%) Controls (%) OR (95%CI)
Variants All subjects Asbestos – exposed only
XRCC1 R399Q (rs25487)
RR 54 (41%) 114 (45%) 1.00 (ref.) 52 (40%) 93 (48%) 1.00 (ref.)
RQ 59 (44%) 113 (45%) 1.34 (0.82–2.19) 59 (45%) 83 (43%) 1.45 (0.89–2.38)
QQ 20 (15%) 25 (10%) 1.88 (0.90–3.92) 20 (15%) 18 (9%) 2.05 (0.97–4.35)
Continuous variable 133 (34.5%) 252 (65.5%) 1.36 (0.97–1.91) 131 (40%) 194 (60%) 1.44 (1.02–2.03)
XRCC1 −77T>C (rs3213245)
TT 49 (37%) 86 (34%) 1.00 (ref.) 49 (37%) 63 (33%) 1.00 (ref.)
TC 67 (50%) 127 (51%) 0.86 (0.52–1.42) 66 (51%) 101 (52%) 0.83 (0.50–1.38)
CC 17 (13%) 39 (15%) 0.69 (0.33–1.44) 16 (12%) 30 (15%) 0.62 (0.29–1.30)
Continuous variable 133 (34.5%) 252 (65.5%) 0.84 (0.59–1.18) 131 (40%) 194 (60%) 0.80 (0.56–1.13)
XRCC1 IVS3 A>C (rs1799778)
AA 54 (40%) 114 (45%) 1.00 (ref.) 52 (40%) 93 (48%) 1.00 (ref.)
AC 58 (44%) 112 (44%) 1.34 (0.82–2.19) 58 (44%) 82 (42%) 1.45 (0.88–2.39)
CC 21 (16%) 26 (10%) 1.85 (0.90–3.81) 21 (16%) 19 (10%) 2.02 (0.97–4.21)
Continuous variable 133 (34.5%) 252 (65.5%) 1.36 (0.97–1.89) 131 (40%) 194 (60%) 1.43 (1.02–2.01)
ERCC1 N118N (rs11615)
TT 43 (32%) 99 (39%) 1.00 (ref.) 43 (33%) 78 (40%) 1.00 (ref.)
TC 71 (53%) 119 (47%) 1.49 (0.90–2.44) 69 (53%) 91 (47%) 1.42 (0.86–2.34)
























Continuous variable 133 (34.5%) 252 (65.5%) 1.24 (0.
oldfaced letters: statistically significant.
a In Casale Monferrato panel, 18 MPM patients were excluded from statistical an
mented changes were identified, but none characterized only
RCC1 399Q or −77C patients.
An association was found also for ERCC1 N118N. Heterozy-
otes (versus wild-type) showed an increased OR both in all
ubjects (OR = 1.66, 95%CI 1.06–2.60) and in asbestos-exposed only
OR = 1.59, 95%CI 1.01–2.50). Homozygotes CC did not show an
ssociation with MPM (probably due to the small size of the group).
hen the dominant model was considered (i.e. ERCC1 heterozy-
otes CT plus homozygotes CC versus homozygotes TT) the risk
o develop MPM conferred by the variant allele C was statistically
ignificant both in all subjects (OR = 1.61, 95%CI 1.06–2.47) and in
sbestos-exposed only (OR = 1.56, 95%CI 1.02–2.40).Meta-analysis was performed for those SNPs that were stud-
ed either by Gemignani et al. [33] or Landi et al. [34] and in this
tudy. We evaluated also the heterogeneity between these studies
nd we found that our study and Gemignani et al. were homo-
eneous, whereas our study and Landi et al. were heterogeneous.
able 4
dds ratios (ORs) and 95% confidence intervals (95%CIs) from multivariate uncondition
ubjects, and by age, gender and panel for the asbestos-exposed subjects in the Casale Mo
Gene SNP (rs) Casesa Controls (%) OR (95%CI)
Variants All subjects
XRCC1 R399Q (rs25487)
RR 85 (42%) 133 (45%) 1.00 (ref.)
RQ 90 (45%) 131 (44%) 1.34 (0.87–2.
QQ 26 (13%) 31 (11%) 1.50 (0.76–2.
Continuous variable 201 (40.5%) 295 (59.5%) 1.26 (0.93–1.
XRCC1 −77T>C (rs3213245)
TT 75 (37%) 104 (35%) 1.00 (ref.)
TC 99 (49%) 144 (49%) 0.89 (0.57–1.
CC 27 (14%) 47 (16%) 0.63 (0.33–1.
Continuous variable 201 (40.5%) 295 (59.5%) 0.82 (0.60–1.
ERCC1 N118N (rs11615)
TT 64 (32%) 117 (40%) 1.00 (ref.)
TC 103 (51%) 137 (46%) 1.66 (1.06–2
CC 34 (17%) 42 (14%) 1.47 (0.79–2.
Continuous variable 201 (40.5%) 296 (59.5%) 1.30 (0.96–1.
oldfaced letters: statistically significant.
a In Casale Monferrato panel, 18 MPM patients were excluded from statistical analyses
re not available for Turin panel.4) 133 (40%) 194 (60%) 1.24 (0.88–1.74)
because of an undefined asbestos exposure.
Consequently, we here presented only data of meta-analysis with
Gemignani et al. A total of 252 patients and 356 controls were
included in this meta-analysis (Table 5 and Table S4). Asbestos
exposure could not be considered. Interestingly, APEX D148E and
ERCC1 N118N showed a statistically significant association with
MPM (APEX EE homozygotes OR = 1.72, 95%CI 1.02–2.91; ERCC1
118N heterozygotes OR = 1.51, 95%CI 1–2.26).
XRCC1 R399Q was not associated to MPM in this meta-analysis
(Table S4).
3.3. The combination of ERCC1 N118N and XRCC1 R399Q
polymorphismsIn order to evaluate the joint effect of ERCC1 and XRCC1 polymor-
phisms, we divided subjects into four groups. We defined ERCC1
TT genotype and XRCC1 GG genotypes as reference group. The
group with at least one variant allele for both polymorphisms
al logistic regression adjusted by age, gender, panel and asbestos exposure for all
nferrato and Turin panel together.
Cases (%) Controls (%) OR (95%CI)
Asbestos – exposed only
82 (41%) 105 (48%) 1.00 (ref.)
07) 90 (46%) 92 (42%) 1.46 (0.94–2.27)
95) 26 (13%) 21 (10%) 1.67 (0.83–3.34)
71) 198 (47.5%) 218 (52.5%) 1.34 (0.98–1.84)
75 (38%) 70 (32%) 1.00 (ref.)
39) 98 (49%) 111 (51%) 0.85 (0.54–1.34)
20) 25 (13%) 37 (17%) 0.52 (0.27–1.01)
10) 198 (47.5%) 218 (52.5%) 0.75 (0.55–1.03)
64 (32%) 90 (41%) 1.00 (ref.)
.60) 100 (51%) 99 (45%) 1.59 (1.01–2.50)
73) 34 (17%) 30 (14%) 1.49 (0.79–2.79)
74) 198 (47.5%) 219 (52.5%) 1.29 (0.96–1.75)
because of an undefined asbestos exposure. Data for XRCC1 IVS3 A>C (rs 1799778)
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Table 5
Meta-analysis of our data and Gemignani’ data [33].




Casale Monf.to 1.63 0.85–3.1 0.779
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XRCC1 haplotype analysis: frequencies in cases and controls and OR (95%CI) adjusted
for age and gender.
Haplotypea Cases (%)b Controls (%)b OR (95%CI)
TGGGGGAACAGA 87 (33.2%) 104 (26.9%) 1 (ref.)
CGGAGGCGCGGA 40 (15.3%) 75 (19.4%) 0.57 (0.34–0.96)
CGGGGGCGCGGA 58 (22.1%) 81 (20.8%) 0.84 (0.53–1.34)
TGGGGGCATGGG 16 (6.1%) 33 (8.5%) 0.61 (0.31–1.19)
TGGGGGCACGCA 14 (5.3%) 28 (7.2%) 0.58 (0.28–1.2)
TGGGGCCACGGA 13 (5%) 20 (5.1%) 0.71 (0.32–1.60)
TGGGGGCACGGA 11 (4.2%) 17 (4.3%) 0.84 (0.35–2.04)
TTGGGGAACAGA 9 (3.4%) 12 (3.1%) 0.94 (0.36–2.48)
Boldfaced letters: statistically significant.
a The haplotype is defined as the allele present at position −77 (T>C, rs3213245),
IVS2 (G>T, rs3213247), IVS2 (A>G, rs129763352), IVS2 (A>G, rs2854496), codon




Gemignani et al. 1.54 0.78–3.03
Pool 1.51 1.00–2.26
oldfaced letters: statistically significant.
howed a statistically significant association with MPM in asbestos
xposed subjects both in Casale Monferrato panel (OR = 2.02, 95%CI
.01–4.05) and in Casale Monferrato and Turin pooled (OR = 2.39,
5%CI 1.29–4.43) (Table 6).
Indexes of sinergy, measured as departure from additive inter-
ction [39], were not statistically significant.
.4. Haplotype analysis
The XRCC1 haplotypes were characterized by nine tag SNPs
identified by Haploview v4.1 on HapMap CEU panel, release #24)
nd three other SNPs that we analyzed previously (rs3213245,
s1799782, rs25487). The pairwise linkage disequilibrium (D′ and
2 values) between XRCC1 genetic markers in the controls group of
he Casale Monferrato panel is shown in Fig. S1.
We estimated haplotype frequencies for cases and controls
y the SHEsis software platform. We considered only haplotypes
ith a frequency >3%. Results are reported in Table 7. The XRCC1-
GGGGGAACAGA haplotype was more represented in cases than
n controls. Among the subjects exposed to asbestos (131 cases,
94 controls) that haplotype was significantly associated with an
ncreased risk to develop MPM (OR = 1.76, 95%CI 1.04–2.96).
We analyzed also the haplotypes that encompassed ERCC1 and
he adjacent gene RAI. Overall we examined six tag SNPs (iden-
ified by Haploview v4.1) and a further SNP of the region (i.e.
able 6
he combination of ERCC1 N118N and XRCC1 R339Q polymorphisms.
XRCC1 combined with ERCC1 genotypes Cases (%) Controls (%) OR (95%
All subjects
Casale Monferrato panel
GG + TT 20 (13%) 46 (18%) 1.00 (re
GG + CC GG + CT 43 (29%) 68 (27%) 1.24 (0
AA + TT GA + TT 27 (18%) 53 (21%) 1.19 (0
AA + CT AA + CC GA + CC GA + CT 61 (40%) 85 (34%) 1.97 (0
Casale Monferrato + Turin panels
GG + TT 30 (14%) 59 (20%) 1.00 (re
GG + CC GG + CT 65 (30%) 74 (25%) 1.92 (1
AA + TT GA + TT 38 (17%) 58 (20%) 1.65 (0
AA + CT AA + CC GA + CC GA + CT 87 (39%) 104 (35%) 2.31 (1
oldfaced letters: statistically significant.rs3213356), codon 194 (C>T, rs1799782), codon 399 (G>A, rs25487), IVS10 (C>G,
rs3213371), +816 (A>G, rs3213403).
b Haplotype frequencies analyzed by SHEsis software platform. Haplotypes with
frequencies <3% in both cases and controls are dropped.
rs11615). No haplotype was found significantly associated (data not
shown).
3.5. FPRP
FPRP was estimated for significant results pertaining XRCC1
R399Q, XRCC1 −77T>C, XRCC1 IVS3, ERCC1 N118N and XRCC1 hap-
lotype. Data are reported in supplementary Table S5.
3.6. Expression analysis
Since XRCC1 −77T>C (rs3213245) is located into the gene
promoter and affects a Sp1 binding site, we evaluated mRNA
expression levels from seventy-one normal pleural tissues. All the
samples were genotyped for XRCC1 −77T>C and the analyses were
performed considering CC genotype as reference group. When we
compared the different genotypes (i.e. 29 TT, 27 CT, 15 CC), for vari-
ation in gene expression level, the difference was not statistically
significant (p = 0.3).
4. Discussion
Our group was the first one to identify an association between
MPM and a DNA repair gene, XRCC1, on the basis of an a pri-
ori hypothesis on the mechanism of damage from asbestos fibers.
Our study suggested that a decreased response to DNA damage
may favour asbestos carcinogenicity [16]. More recently, by using
a custom-made SNP microarray another Italian group studied 50
SNPs in xenobiotic and oxidative metabolism enzymes (XME) genes
and 76 SNPs in genes involved in genome stability (GS) in a panel
that included 119 MPM patients and two groups of controls (104
CI) Cases (%) Controls (%) OR (95%CI)
Asbestos –exposed only
f.) 19 (15%) 37 (19%) 1.00 (ref.)
.60–2.54) 33 (25%) 56 (29%) 1.12 (0.54–2.32)
.55–2.58) 24 (18%) 41 (21%) 1.21 (0.56–2.62)
.99–3.92) 55 (42%) 60 (31%) 2.02 (1.01–4.05)
f.) 29 (14%) 47 (21%) 1.00 (ref.)
.02–3.64) 53 (27%) 58 (27%) 1.76 (0.92–3.34)
.83–3.29) 35 (18%) 43 (20%) 1.68 (0.84–3.38)
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ith and 695 without documented asbestos exposure). Statisti-
al analysis showed a significant association with the nucleotidic
hange 282C>T within NAT2 [33], reinforcing existing evidences
hat genetic polymorphisms are possibly involved in the etiology
f MPM [40]. That observation is difficult to explain biologically
ecause the mechanism by which NAT2 may influence asbestos
arcinogenicity is not clear. Some of the studied DNA repair genes
evealed significant associations, but most of them disappeared
fter Bonferroni correction for multiple analyses. A further study
rom the same group reported an association with SOD2 16A
34].
To extend previous observation we investigated the associa-
ion of 35 SNPs with MPM in a panel of 220 Italian patients and
96 controls whose asbestos exposure had been accurately evalu-
ted. The largest portion of patients and controls were from Casale
onferrato, a town whose population experienced widespread,
on-occupational exposure to asbestos, additional to that of work-
rs employed in the local asbestos-cement factory. It is expected
hat this situation should reveal genetic susceptibility by increasing
enetrance.
Only two genes were found significantly associated with MPM,
.e. XRCC1 and ERCC1, both involved in DNA repair.
Although our study design has some limitations (e.g. low
esponse rate and selection of patients) the XRCC1 R399Q, XRCC1
VS3 and XRCC1 haplotype associations showed an acceptable level
f false reports with a prior probability of 0.25 and an expected OR
f 1.5. However, the XRCC1 −77T>C and ERCC1 N118N associations
howed a low level of false reports only with an expected OR of 2.0
power = 97%).
A dosage effect, suggestive of a dominant model, was shown for
RCC1 399Q.
The meta-analysis with the data on XRCC1 and ERCC1 by
emignani et al. [33], regardless of asbestos exposure, confirmed
nd extended our results. XRCC1 R399Q, evaluated on all individ-
als independently from asbestos exposure, is not associated to
PM, like in the Casale Monferrato and Turin serie. Thus, XRCC1
399Q seems to be a risk factor only for asbestos-exposed subjects.
onversely, the meta-analysis confirmed our data and showed that
RCC1 N118N is a risk factor per se.
Haplotypes for both XRCC1 and ERCC1 were also evaluated, but
nly the XRCC1-TGGGGGAACAGA haplotype was found statistically
ignificative, being more represented in cases than in controls. Our
ata seem to favour the hypothesis that the effect of the contiguous
enes XRCC1 and ERCC1 is not due to LD.
Sequencing of the promoter and coding region of XRCC1 in
atients and controls did not reveal another DNA change in LD with
he R399Q that could functionally explain the association. Thus the
ssociation should be due to the studied SNPs or to other SNPs
ocated in the non-sequenced regions.
Both XRCC1 R399Q and ERCC1 N118N have been found associ-
ted with cancer in different studies [41–47]. The combination of
RCC1 and XRCC1 polymorphisms better predicts clinical outcome
o oxaliplatin-based chemotherapy in metastatic colorectal cancer
48]. However, little is known about the functional effect of these
NPs.
Epidemiological association studies, performed on different
ancer types, have often been inconclusive or contradictory. The
RCC1 -399Q variant has been associated with lung cancer [41],
reast cancer [42,43], colorectal cancer [44], prostate cancer [45],
ut not with bladder cancer [49].
Functional studies pointed out that XRCC1 -399Q may be
ssociated with increased DNA damage measured by aflatoxin B1-
NA adducts, glycophorin A (GPA) variant frequency [50], sister
homatid exchange and polyphenol DNA adducts [51]. Moreover,
arriers of the 399Q variant showed a significant increase in chro-
osomal deletions in whole-blood cells [52].arch 708 (2011) 11–20
Differently, the 399R and 399Q equally complement both the
single-strand break repair defect and the sensitivity to methyl
methanesulfonate (MMS) in vitro in XRCC1-deficient CHO cells, sug-
gesting that the 399Q variant retained a substantial level of function
in those experimental conditions [53].
Interestingly, R399Q is located in the BRCT1 domain, i.e. the
poly (ADP-ribose) polymerase I (PARP) interaction site. The three-
dimensional structure of the wild-type XRCC1-BRCT1 domain is
characterized by four  helices and three  sheets. The predicted
structure of the variant 399Q protein shows the absence of three
 helices and two  sheets. This suggests that 399Q may induce
a significant conformational change in the BRCT domain. Since 
helices are involved in protein–protein interactions, it is possible
that the 399Q variant modifies the scaffold function of XRCC1 [54].
Moreover, the XRCC1 haplotype that is associated to MPM
includes another SNP that may have functional relevance. The
−77T>C SNP is located in the promoter region of XRCC1 within
the core of a predicted Sp1-binding sequence. Sp1 is a zinc-finger
transcription factor that may act as a transcriptional repressor or
activator, depending on the context. Using several non-pleural cell
lines Hao et al. [55] demonstrated that the −77C allele has an high
affinity to Sp1, but is associated with a reduced transcriptional
activity in vitro. They concluded that Sp1 acts as a transcriptional
repressor of XRCC1 expression and that the reduced XRCC1 expres-
sion due to the C allele may be the reason of its association with
lung [56,57] and gastric cancer [58].
On the contrary, our results show that −77C plays a protective
role for MPM. Since −77T and 399Q lie on the same at-risk hap-
lotype our hypothesis was that the reduced Sp1 affinity due to
the −77T allele may cause an increased expression of the 399Q
variant protein leading to an impaired function, such as abnormal
interactions with other DNA repair protein of the BER complex.
However, no data are available for expression of XRCC1 in pleu-
ral tissues relative to specific XRCC1 genotypes. To ascertain our
hypothesis we analyzed XRCC1 expression in genotyped healthy
subjects using real-time PCR. Our data do not suggest an effect of
this SNP on XRCC1 expression on pleural tissues. However, we eval-
uated expression in pleural tissue as a whole, not specifically in
mesothelial primary cell cultures.
Controversial epidemiological association studies are also evi-
dent for ERCC1 N118N. This SNP has been associated with response
to treatment of lung cancer [46], but not with colorectal cancer [59].
On the other hand, a study of some authors of this paper showed
that not only the ERCC1 N118N, but also ERCC1 haplotypes modify
bladder cancer risk [47].
The ERCC1 gene and the XRCC1 gene are located close one
another (approximately 2 Mb apart). Hoeijmakers et al. [60] found
that ERCC1 3′-terminus overlapped with the 3′-end of another
gene, designated ASE1. This exceptional type of gene overlap
was conserved in mouse and even in the yeast ERCC1 homolog,
RAD10, suggesting an important biologic function of this region
(19q13.2–q13.3). Besides, haplotypes in this region have been
found associated with increased cancer risk [61–65]. Although
we have found an association between MPM and a XRCC1 hap-
lotype and a cumulative of XRCC1 and ERCC1 variants, we have
not observed an association with ERCC1 haplotypes. The biological
mechanisms that explain the association of these SNPs with MPM
are still obscure.
Interestingly, our meta-analysis shows that also another DNA
repair gene, APEX, is associated to MPM using the codominant
model. APEX is part of BER, as XRCC1 [66]. More data are needed
to ascertain this association.
In conclusion, this study shows an association between two DNA
repair genes and MPM and strengthen the hypothesis of a role for
genetic risk factors in asbestos carcinogenicity. It should be stressed
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isk caused by asbestos exposure itself (OR of 50–100 for asbestos
ersus 1–2 for genetic factors).
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